ALS Association: Lawrence and Isabel Barnett Drug Development Program (LOI)

Projects of Interest

Both novel programs and repurposing of approved or clinically safe therapies from other disease indications are appropriate for this funding opportunity. Especially interested in:

• In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapies) in models of ALS.

• Studies focused on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement.

• Other Investigational New Drug (IND)-enabling studies.

Funding:  These grants provide up to $500,000 over two years to support the crucial transition from laboratory research project to industry drug development effort

Lawrence and Isabel Barnett Drug Development Program